| scholarly article | Q13442814 |
| P2093 | author name string | Michael T Nurmohamed | |
| Inge A M van den Oever | |||
| Alper M van Sijl | |||
| P2860 | cites work | Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 |
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis | Q24601392 | ||
| Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity | Q24630655 | ||
| Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis | Q24801010 | ||
| Cardiovascular risk factors in women with and without rheumatoid arthritis | Q28171426 | ||
| Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction | Q28185974 | ||
| Simvastatin improves endothelial function in patients with rheumatoid arthritis | Q45244385 | ||
| The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs | Q45368493 | ||
| Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. | Q45781042 | ||
| The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study | Q45792532 | ||
| Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. | Q46003173 | ||
| Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. | Q46111865 | ||
| Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study | Q46113236 | ||
| Insulin resistance and impaired beta cell function in rheumatoid arthritis | Q46161578 | ||
| Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation | Q46433523 | ||
| Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. | Q46787385 | ||
| Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. | Q46838483 | ||
| Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. | Q46852341 | ||
| Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. | Q50701881 | ||
| Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial | Q51652663 | ||
| Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. | Q51922378 | ||
| Cyclooxygenase inhibitors and the antiplatelet effects of aspirin | Q28191912 | ||
| General cardiovascular risk profile for use in primary care: the Framingham Heart Study | Q29614189 | ||
| Obesity and physical activity: a review | Q33234949 | ||
| Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. | Q33307666 | ||
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
| Homocysteine and coronary heart disease: a review of the current evidence | Q33764434 | ||
| Cardiovascular morbidity and mortality in rheumatoid arthritis | Q33806651 | ||
| Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. | Q33908100 | ||
| Total cholesterol and LDL levels decrease before rheumatoid arthritis | Q33931317 | ||
| Infection and inflammation-induced proatherogenic changes of lipoproteins | Q33935040 | ||
| Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women | Q34067367 | ||
| Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis | Q34125171 | ||
| The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases | Q34129198 | ||
| Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation | Q34150320 | ||
| Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness | Q34153114 | ||
| Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study | Q34183822 | ||
| Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics | Q34233328 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear? | Q34284357 | ||
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 | ||
| Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis | Q34348857 | ||
| The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population. | Q34398263 | ||
| Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis | Q34401259 | ||
| The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review | Q34418795 | ||
| Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. | Q34461548 | ||
| Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project | Q34534248 | ||
| Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension | Q34582036 | ||
| Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 | ||
| Cachexia in rheumatoid arthritis | Q34774438 | ||
| Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 | ||
| Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study | Q34897630 | ||
| Cigarette smoking and rheumatoid arthritis severity | Q35547371 | ||
| Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis | Q35548424 | ||
| Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension | Q35551644 | ||
| The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37640953 | ||
| Obesity, inflammation, and cardiovascular risk | Q37702091 | ||
| Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review | Q37753155 | ||
| Incident Comorbidity Among Patients with Rheumatoid Arthritis Treated or Not with Low-dose Glucocorticoids: A Retrospective Study | Q37789100 | ||
| Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis | Q37801353 | ||
| Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37808889 | ||
| The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis | Q37987963 | ||
| Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis | Q39959053 | ||
| Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. | Q40258187 | ||
| Therapy with statins in patients with refractory rheumatic diseases: a preliminary study | Q40551294 | ||
| Comorbidity in arthritis. | Q40790498 | ||
| Exercise in the management of non-insulin-dependent diabetes mellitus | Q41698189 | ||
| Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis | Q42165744 | ||
| Leflunomide and hypertension | Q43051153 | ||
| Insulin resistance in early untreated rheumatoid arthritis patients | Q43167068 | ||
| Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. | Q43426783 | ||
| Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones | Q43922538 | ||
| Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease | Q44204800 | ||
| The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). | Q44400392 | ||
| Glucocorticoids and insulin sensitivity in rheumatoid arthritis | Q44881615 | ||
| Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
| Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease | Q45151895 | ||
| Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement | Q45167242 | ||
| Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? | Q45235877 | ||
| Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. | Q53249650 | ||
| Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. | Q53548272 | ||
| Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. | Q53923887 | ||
| Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. | Q54389817 | ||
| Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis. | Q54568998 | ||
| Smoking and risk of rheumatoid arthritis. | Q55066113 | ||
| Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism | Q57300335 | ||
| Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study | Q57689262 | ||
| Are Patients With Rheumatoid Arthritis Less Physically Active Than the General Population? | Q57788745 | ||
| Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort | Q57804967 | ||
| Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study | Q58160099 | ||
| Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis | Q59394199 | ||
| Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study | Q60298067 | ||
| Atherosclerosis in Rheumatoid Arthritis Versus Diabetes | Q60594020 | ||
| Exercise training combined with antihypertensive drug therapy. Effects on lipids, blood pressure, and left ventricular mass | Q68769119 | ||
| Physical activity, physical fitness, and all-cause mortality in women: do women need to be active? | Q70503292 | ||
| Low physical activity reduces total energy expenditure in women with rheumatoid arthritis: implications for dietary intake recommendations | Q77220887 | ||
| High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors | Q77406810 | ||
| Functional status predicts mortality in a community based rheumatoid arthritis population | Q77436035 | ||
| Lipid profiles in untreated patients with rheumatoid arthritis | Q78139431 | ||
| Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis | Q79698753 | ||
| Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study | Q79850163 | ||
| Comparison of energy expenditure from lifestyle physical activities between patients with rheumatoid arthritis and healthy controls | Q80244009 | ||
| Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study | Q80791227 | ||
| Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis | Q80808131 | ||
| Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis | Q80843926 | ||
| Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation | Q80932706 | ||
| Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis | Q80969856 | ||
| Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? | Q81312678 | ||
| Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis | Q81412936 | ||
| Cardiovascular death in rheumatoid arthritis: a population-based study | Q81484761 | ||
| Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis | Q82299864 | ||
| Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study | Q83355833 | ||
| Dyslipidaemia in patients with seropositive arthralgia predicts the development of arthritis | Q84131903 | ||
| Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic | Q85777778 | ||
| Different type of carotid arterial wall remodeling in rheumatoid arthritis compared with healthy subjects: a case-control study | Q87400076 | ||
| Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis | Q35553035 | ||
| Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. | Q35553700 | ||
| Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s | Q35554980 | ||
| Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. | Q35582724 | ||
| Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
| Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs | Q35636594 | ||
| Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis | Q35638369 | ||
| Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis | Q35638659 | ||
| Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. | Q35855164 | ||
| Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis | Q36030664 | ||
| Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. | Q36031031 | ||
| Atherosclerosis and rheumatoid arthritis: more than a simple association | Q36253671 | ||
| Protective effects of angiotensin II interruption: evidence for antiinflammatory actions | Q36257966 | ||
| Inflammation and cardiovascular disease mechanisms | Q36392615 | ||
| Reducing the cardiovascular disease burden in rheumatoid arthritis | Q36426046 | ||
| Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis | Q36464352 | ||
| Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women | Q36496352 | ||
| Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis | Q36511541 | ||
| Atherogenic lipid profiles and its management in patients with rheumatoid arthritis | Q36596894 | ||
| Cigarette smoking and autoimmune disease: what can we learn from epidemiology? | Q36677000 | ||
| Abdominal obesity and metabolic syndrome | Q36682671 | ||
| Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study | Q36757060 | ||
| Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis | Q36955395 | ||
| Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. | Q37079259 | ||
| Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. | Q37129611 | ||
| Rheumatoid cachexia: a clinical perspective | Q37151582 | ||
| Hypertension in rheumatoid arthritis. | Q37158219 | ||
| The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis | Q37173846 | ||
| Role of inflammation in atherosclerosis associated with rheumatoid arthritis | Q37300182 | ||
| Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms | Q37371379 | ||
| Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis | Q37401378 | ||
| An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs | Q37465540 | ||
| Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment | Q37533298 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| circulatory system | Q11068 | ||
| P304 | page(s) | 166-181 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Therapeutic advances in musculoskeletal disease | Q26841913 |
| P1476 | title | Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion | |
| P478 | volume | 5 |
| Q41670041 | Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis. |
| Q26864064 | Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators |
| Q54255528 | Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients. |
| Q38568465 | Cardiovascular comorbidity in rheumatic diseases |
| Q38653041 | Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database |
| Q38936667 | Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis. |
| Q58107097 | Common atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration |
| Q41225289 | Does depression increase the risk of stroke in patients with rheumatoid arthritis? A population-based cohort study. |
| Q37723594 | Lipid abnormalities in patients with Rheumatoid Arthritis |
| Q38554197 | Lipid and Metabolic Changes in Rheumatoid Arthritis. |
| Q38580767 | Non-invasive assessment of arterial stiffness in patients with rheumatoid arthritis: a systematic review and meta-analysis of literature studies |
| Q38628320 | Nurses' Role in Cardiovascular Risk Assessment and Management in People with Inflammatory Arthritis: A European Perspective |
| Q64093765 | Plasma from Patients with Rheumatoid Arthritis Reduces Nitric Oxide Synthesis and Induces Reactive Oxygen Species in A Cell-Based Biosensor |
| Q41464826 | Prevalence of Asymptomatic Arterial Hypertension and Its Correlation with Inflammatory Activity in Early Rheumatoid Arthritis. |
| Q38612651 | Prevention of Stroke in Rheumatoid Arthritis |
| Q40150234 | Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis |
| Q53827279 | Variables associated with subclinical atherosclerosis in a cohort of rheumatoid arthritis patients: Sex-specific associations and differential effects of disease activity and age. |
| Q37673292 | Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. |
Search more.